IceCure Medical Receives New Patent In China For Covering A Connector Used In Its Cryogenic Technology Platform

IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, announced today that the China National Intellectual Property Administration ("CNIPA") has granted the Company a new patent in China, covering a connector used in its cryogenic technology platform, further expanding IceCure's global intellectual property portfolio and strengthening the protection of its proprietary cryogenic technologies in key international markets.